Oral Anticoagulants and Nonvalvular A-fib: A Balancing Act
Although accreditation for this CE/CME activity has expired, and the posttest is no longer available, you can still read the full article.
Expires February 29, 2016
Patients with nonvalvular atrial fibrillation (A-fib) have a fivefold greater risk for ischemic stroke than those without. Newer oral anticoagulants reduce this risk—but also increase risk for serious bleeding, including intracranial hemorrhage. Here are the evidence-based guidelines to help you make the choice that’s best for your patient.
CONCLUSION
Nonvalvular A-fib is a common arrhythmia that contributes significantly to morbidity among older adults. Use of the most current clinical practice guidelines coupled with patient education will improve overall patient outcomes.
* Editor's note: At press time, the FDA had announced approval of another oral anticoagulant, edoxaban, for the reduction of stroke and systemic embolism risks in nonvalvular A-fib.
